Oncometabolites

Citation for published version:

Digital Object Identifier (DOI):
10.1172/JCI67228

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published In:
Journal of Clinical Investigation

Publisher Rights Statement:
© 2013, American Society for Clinical Investigation

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Oncometabolites: linking altered metabolism with cancer

Ming Yang,1 Tomoyoshi Soga,2,3 and Patrick J. Pollard1,4

1Cancer Biology and Metabolism Group, Nuffield Department of Medicine, Henry Wellcome Building for Molecular Physiology, University of Oxford, Oxford, United Kingdom. 2Institute for Advanced Biosciences and 3Oxford-Keio Metabolomics Consortium, Keio University, Yamagata, Japan. 4Oxford-Keio Metabolomics Consortium, Oxford, United Kingdom.

The discovery of cancer-associated mutations in genes encoding key metabolic enzymes has provided a direct link between altered metabolism and cancer. Advances in mass spectrometry and nuclear magnetic resonance technologies have facilitated high-resolution metabolite profiling of cells and tumors and identified the accumulation of metabolites associated with specific gene defects. Here we review the potential roles of such “oncometabolites” in tumor evolution and as clinical biomarkers for the detection of cancers characterized by metabolic dysregulation.

Introduction

The emerging interest in metabolites whose abnormal accumulation causes both metabolic and nonmetabolic dysregulation and potential transformation to malignancy (herein termed “oncometabolites”) has been fueled by the identification of cancer-associated mutations in genes encoding enzymes with significant roles in cellular metabolism (1–5). Loss-of-function mutations in genes encoding the Krebs cycle enzymes fumarate hydratase (FH) and succinate dehydrogenase (SDH) cause the accumulation of fumarate and succinate, respectively (6), whereas gain-of-function isocitrate dehydrogenase (IDH) mutations increase levels of D-2-hydroxyglutarate (D-2HG) (7, 8). These metabolites have been implicated in the dysregulation of cellular processes including the competitive inhibition of α-ketoglutarate–dependent dioxygenases (enzymes also known as 2-oxoglutarate–dependent dioxygenases) and posttranslational modification of proteins (1, 4, 9–11). To date, several lines of biochemical and genetic evidence support roles for fumarate, succinate, and D-2HG in cellular transformation and oncogenesis (3, 12).

Production of oncometabolites in cancer

D-2HG accumulates to millimolar concentrations in tumors with monoallelic mutations in IDH1 and IDH2 (8). There are three IDH isoforms in humans: IDH1 and IDH2 are NADP+-dependent homodimers localized in the cytoplasm and mitochondria, respectively, that catalyze the reversible conversion of isocitrate to α-KG, whereas IDH3 is an NAD+-dependent heterotetramer and catalyzes the irreversible oxidative decarboxylation of isocitrate to α-KG in the Krebs cycle (13). Somatic mutations in IDH1 and IDH2 occur in multiple human cancers, including low-grade glioma and secondary glioblastoma, chondrosarcoma, cholangiocarcinoma, and acute myeloid leukemia (AML) (14–19). The most common cancer mutations map to single arginine residues in the catalytic pockets: IDH1 (R132) and IDH2 (R172 or R140) (16, 19, 20). Mutant IDH1/2 forms a dimer with the wild-type copy derived from the normal allele and displays a neomorphic activity that allows the heterodimeric enzyme to catalyze the reduction of α-KG directly to D-2HG in the presence of NADPH (refs. 7, 8, 21, 22, and Figure 1).

Succinate and fumarate accumulation occur in tumors driven by inactivating mutations in SDH and FH, the gene products of which catalyze sequential steps in the Krebs cycle. SDH mutations are commonly found in hereditary paraganglioma (PGL) and pheochromocytoma (PCC), while FH mutations are associated with hereditary leiomyomatosis and renal cell cancer (HLRCC) (23). Affected individuals inherit a loss-of-function mutation in one allele, with their tumors displaying loss of heterozygosity in the other allele, usually through somatic deletion or chromosomal loss; thus both genes follow the hereditary pattern of typical tumor suppressors (24). SDH is a highly conserved heterotetrameric protein, with SDHA and SDHB as catalytic subunits and SDHC and SDHD as ubiquinone-binding and membrane-anchor subunits. In addition to its role in the Krebs cycle, SDH also functions as complex II of the electron transport chain (ETC), catalyzing the oxidation of succinate to fumarate in a reaction that generates FADH2, and donates electrons to the ETC. Mutations in genes encoding SDH subunits as well as the SDH assembly factor 2 occur frequently in PGL/PCC, but have also been identified in other types of tumors such as gastrointestinal stromal tumors (GISTs), renal tumors, thyroid tumors, testicular seminomas, and neuroblastomas (25). FH exists as a homotetrameric enzyme that catalyzes the stereospecific and reversible hydration of fumarate to malate. Though characterized by renal cancer, renal cysts, and skin and uterine leiomyomas (26, 27), evidence suggests that FH mutations may also be involved in the pathogenesis of breast, bladder, and Leydig cell tumors (28, 29). Both SDH and FH mutations significantly reduce their enzymatic activities, leading to accumulation of high levels of succinate and fumarate, respectively (refs. 6, 30–32, and Figure 2).

Epigenetic alterations

A common oncogenic mechanism linking D-2HG, succinate, and fumarate is the inhibition of α-KG–dependent dioxygenases (9), particularly of the Jumonji C domain–containing histone lysine demethylases (KDMs) and the ten eleven translocation (TET) family of S-methylcytosine (5mC) hydroxylases, which results in epigenetic alterations that affect the expression of genes involved in cell differentiation and the acquisition of malignant features (Figures 1 And 2). Turcan et al. showed that D-2HG accumulation in IDH1-mutant gliomas substantially remodeled the DNA methylome and established a distinct CpG island methylator phenotype, which can be phenocopied by the stable expression of

Conflict of interest: Tomoyoshi Soga is a founder of Human Metabolome Technologies.

Citation for this article: j Clin Invest. 2013;123(9):3652–3658. doi:10.1172/JCI67228.
IDH1 R132H in primary human astrocytes (33). Elevated DNA methylation is also observed in AML samples harboring either 2HG-producing mutations in IDH1/2 or inactivating mutations in the α-KG–dependent TET2 enzyme (34, 35), and expression of mutant IDH1/2 or treatment with D-2HG is sufficient to inhibit TET2 function and impair differentiation in erythroleukemia cells (36). Expression of IDH mutants also suppressed histone demethylation, which repressed the expression of genes involved in lineage-specific differentiation and impaired adipocyte differentiation in culture (37). Taken together, these observations suggest that D-2HG acts as an oncogenic driver via epigenetic reprogramming in IDH-associated cancers.

Succinate and fumarate have been shown to inhibit KDM and TET enzymes in vitro and in cultured cells, leading to enhanced histone methylation marks and decreased global 5-hydroxymethylcytosine (5hmC) levels (38). Recently, two independent studies both demonstrated that succinate could also remodel the cancer epigenome. Killian et al. studied the methylation profiles of GIST tumors driven by mutations in either SDH or KIT and uncovered substantial DNA hypermethylation in the SDH-mutant subgroup (39). The authors also examined PGL/PCC tumors and identified hypermethylation in those harboring SDH mutations (39). In parallel, Letouzé and colleagues classified the methylation status of a large PGL/PCC cohort and identified a distinct epigenetic subcluster characterized by a hypermethylator phenotype (40). Strikingly, SDH mutations were discovered in 16 of 17 samples from the hypermethylated subgroup, in which the expression of 191 genes was downregulated concurrently with levels of CpG promoter hypermethylation. Two of the most significantly epigenetically silenced genes, PNMT and KRT19, are involved in neuroendocrine differentiation and epithelial-mesenchymal transition, respectively, which potentially explains the undifferentiated phenotype and aggressive nature of SDH-related PGL/PCC. Furthermore, Sdhb-deficient mouse chromaffin cells exhibit higher 5mC/5hmC ratios compared with wild-type cells, which can be reversed by the addition of exogenous α-KG, supporting the hypothesis that succinate inhibits TET-catalyzed DNA modification. Interestingly, the only tumor in the hypermethylated PGL/PCC subgroup with wild-type SDH harbored germline and somatic FH mutations, strongly suggesting that fumarate may also play a role in epigenetic rewiring in HLRCC (40). Finally, both groups analyzed developmentally distinct tumors containing SDH and IDH mutations and discovered an overlap in their hypermethylation patterns, potentially implicating a shared role for D-2HG, succinate, and fumarate in reprogramming of the epigenetic landscape in cancer.

Pseudohypoxia

In SDH- and FH-deficient cells and tumors, the activation of a HIF-orchestrated “pseudohypoxic” response has been reported (41–44), which could at least in part be attributed to the allosteric inhibition of HIF prolyl hydroxylases (PHDs) by elevated levels of succinate or fumarate (Figure 2). Although generally regarded as a major player in human cancer by transcriptionally regulating pathways that facilitate tumor growth and progression, the exact role of HIF in tumorigenesis is unclear (45). At least in the context of FH deficiency, a causal role for HIF in cancer initiation is debatable, as indicated by the observation that combined inactivation of Fh1 and Hif1a in mouse renal tubular cells exacerbated the cystic phenotype associated with Fh1 inactivation alone (46). Similarly, there have been contradictory observations of HIF levels in IDH-mutant models. Mice bearing the Idh1 R132H mutant accumulated Hif-1α and upregulated the expression of Hif target genes (47, 48). Ectopic expression of IDH1 R132H also increased Hif-1α levels in HEK293T and U-87MG glioblastoma cells (49, 50). In contrast, Koivunen et al. showed that, whereas L-2HG inhibits PHD activity, D-2HG promotes it by acting as a cofactor for these enzymes at pathophysiological concentrations, leading to diminished HIF levels, which confers a proliferative advantage for human astrocytes in soft agar growth (ref. 51 and Figure 1).

D-2HG is present at low levels in normal cells and can be metabolized by the enantiomer-specific D-2HG dehydrogenase (D2HGDH) to α-KG (52). Accumulation of either D- or L-2HG has been detected in the body fluids of patients with rare metabolic disorders that result from mutations in the corresponding genes encoding D2HGDH and succinate dehydrogenase complex subunits (53). When D-2HG is present at physiologically relevant concentrations, it is a poorer substrate for succinate dehydrogenase. While the precise mechanism of this regulation is unclear, the presence of otherwise low levels of D-2HG in normal tissues may explain the absence of tumors in patients with D2HGDH deficiency.
dehydrogenase D2HGDH or L2HGDH (53, 54). Compared to D-2HG, L-2HG is a more potent inhibitor of the α-KG–dependent dioxygenases tested to date (49, 51). Interestingly, there is an increased risk for pediatric glioma in systemic L2HGDH deficiency, but not in patients with D2HGDH deficiency (53, 55), suggesting that the tumorigenic effect of D-2HG in adult tumors may be context specific or dose dependent. Furthermore, gliomas harboring IDH1/2 mutations are associated with better prognosis (49, 51). Kaelin and colleagues (36) proposed that the seemingly paradoxical observations could potentially be explained by the differential effect of D-2HG on HIF PHDs and histone/DNA demethylases. The authors showed that IDH1 R132H expression promoted growth factor independence and impaired differentiation of erythroleukemia cells, whereas loss of PHD2 activity blocked the leukemic transformation induced by IDH1 R132H expression or TET2 suppression. At tumor-relevant concentrations, D-2HG exerts an inhibitory effect on TET2 and causes epigenetic reprogramming while acting as an agonist for PHDs to promote HIF degradation. Indeed, HIF may have a tumor-suppressive effect at least in this setting, supported by the observations that HIF can inhibit hematopoietic stem cell and leukemic cell proliferation (56, 57).

Collagen maturation
Interestingly, recent work employing a small-molecule inhibitor against IDH1 R132 suggested that D-2HG might promote cancer growth through factors other than its epigenetic effects (58). Potential explanations may include modulation of HIF activity as discussed above, and dysregulation of other α-KG–dependent dioxygenases and corresponding cellular programs. Sasaki et al. showed that mice bearing Idh1 R132H mutations exhibit defects in collagen protein maturation and disrupted basement membrane formation, which could be attributed to D-2HG–mediated inhibition of collagen prolyl and lysyl hydroxylases and may contribute to abnormal tissue morphology and, potentially, glioma progression (47, 48). RNA expression array analyses of mutant IDH1 xenograft tumors also identified alterations in type IV collagen expression (58). Recently, the range of reactions catalyzed by α-KG–dependent dioxygenases has been further extended to ribosome protein modifications (59), and it remains to be determined whether translational processes are also sensitive to D-2HG targeting.

Succination and succinylation
Fumarate is an electrophilic metabolite that can react spontaneously with free sulfhydryl groups in cysteine residues by a Michael addition reaction to produce \( \text{S-(2-succino)-cysteine (2SC)} \), a process termed succination (60, 61). Succination can impair protein function, notably that of Kelch-like ECH-associated protein 1 (KEAP1), which is a major cellular electrophile sensor and negative regulator of the transcription factor nuclear factor E2-related factor 2 (NRF2) (62). Under normal physiological conditions, KEAP1 interacts with NRF2, promoting its ubiquitylation and proteasomal-mediated degradation. In the presence of oxidative stress or electrophiles, the KEAP1-NRF2 interaction is disrupted.
ed, resulting in the nuclear translocation of NRF2 and activation of an assortment of genes involved in antioxidant defense (63, 64). Work from ourselves and others demonstrated that in FH-deficient cells, KEAP1 is succinilated on two critical cysteine residues (Cys155 and Cys288), which abrogates its interaction with NRF2 and elicits the constitutive expression of NRF2 target genes (refs. 46, 65, and Figure 2). Several lines of evidence suggest that activation of the NRF2-mediated antioxidant defense pathway may promote tumorigenesis by enhanced ROS detoxification as well as conferring a more reduced intracellular environment that can promote cell survival and proliferation (66, 67).

This model is also supported by the observations that inactivating KEAP1 mutations and activating NRF2 mutations are found in various human cancers (68) and that NRF2 and its target genes are overexpressed in many cancer cell lines and human tumors (69–71). The identification of the NRF2 target gene heme oxygenase (decycling) 1 (HMOX1), which encodes a protein involved in heme degradation, as synthetically lethal to FH deletion, further supports the hypothesis that NRF2 can promote survival of FH-deficient cells (72), as does the recent discovery of NRF2-activating somatic mutations in sirtuin 1 (SIRT1), cullin 3 (CUL3), and NRF2 in sporadic papillary renal cell carcinomas (translocation associated) type 2 (PRC2) (73).

We recently conducted a proteomic-based screen for novel 2SC targets and identified succinilation in more than 90 proteins in Fh1-deficient mouse embryonic fibroblasts (MEFs) and tissues. Nearly half of the 2SC targets thus identified are involved in metabolic processes, among which we identified the succinilation of the Krebs cycle enzyme aconitase 2 (ACO2) at three cysteine residues that are required for iron-sulfur cluster binding (ref. 74 and Figure 2). Fumarate-mediated succinilation of ACO2 exerted a dose-dependent inhibition on its enzymatic activity in vitro, and Fh1-deficient MEFs displayed reduced aconitase activity compared with wild-type counterparts. In contrast to other cell lines with compromised mitochondrial function, through either mutation or hypoxic stress, Fh1-deficient MEFs did not utilize the reductive carboxylation pathway for citrate synthesis, possibly due to succinilation of ACO2 (74–77). Taken together with previous work demonstrating succinilation and inhibition of GAPDH activity (78), it is plausible that succinilation is widespread in FH deficiency and that fumarate may cause dysregulation of key metabolic proteins, potentially contributing to the oncogenesis of HLRCC.

Succinination is a distinct process from succinylation, which typically occurs on lysine residues and is considered to be mediated by succinyl coenzyme A, producing a thioester derivative protein product (79). Recently, increases in protein succinylation have also been shown to occur under conditions where succinate levels are elevated and the activity of the desuccinylase SIRT5 is suppressed. Succinylated proteins targets identified include malate dehydrogenase, GAPDH, glutamate carrier 1, L-lactate dehydrogenase A chain and transaldolase (80). Protein succinylation levels and functional consequences in SDH-mutant tumors are interesting topics for future investigation.

**ROS**

Dysregulation of mitochondrial function characterized by Krebs cycle defects has been associated with overproduction of ROS, which may participate in oncogenic signaling and tumor progression by irreversible modification of DNA and oxidation of proteins (81, 82). Mouse fibroblasts transfected with an SDHC mutant displayed sustained ROS production and elevated DNA mutation frequency (81). A separate study using hamster fibroblasts expressing a truncated form of SDHC also showed increased steady-state levels of ROS and genomic instability (83). Guzy and colleagues further proposed that ROS-induced inactivation of PHDs triggers the HIF response in SDH-deficient cells, thus providing an alternative model for HIF activation in SDH deficiency (84).

Cells harboring 2HG-producing IDH mutations manifest depleted cellular glutamate levels, possibly because the metabolite is shunted to produce α-KG and subsequently converted to D-2HG, and elevated NADP+/NADPH ratios as a result of impaired generation but increased consumption of NADPH (3). Both events could suppress glutathione synthesis and regeneration in IDH mutant cells (85), potentially conferring an oxidative intracellular status and affecting biosynthesis. Surprisingly, Idh1 R132H–expressing mouse brain cells displayed attenuated ROS levels despite an increased NADP+/NADPH ratio (47).

Very recently, Sullivan et al. showed that succinilation of the antioxidant glutathione by fumarate in FH-deficient cells results in the accumulation of succinated glutathione, which acts as an alternative substrate to glutathione reductase, leading to decreased NADPH levels, enhanced mitochondrial ROS, and HIF-1α stabilization (86). Interestingly, the authors showed that fumarate-dependent succinilation, rather than ROS-induced oxidation, of KEAP1, is the dominant mechanism for NRF2 activation in these cells. The NRF2-mediated antioxidant pathways in turn serve to mitigate enhanced ROS levels, thus reflecting the intricate adaptive mechanisms of FH-deficient cells in combating redox stress.

**Fumarate-dependent dysregulation of the urea cycle**

The identification of KEAP1 succinilation suggests that fumarate accumulation occurs in subcellular compartments other than mitochondria in FH-deficient cells. In addition to its role in the Krebs cycle, fumarate also participates in the urea cycle and the purine biosynthesis pathway (refs. 87–90 and Figure 2). Recently it has been reported that fumarate accumulation can cause reversal of the argininosuccinate lyase–catalyzed reaction in the urea cycle, resulting in accumulation of fumarate-derived argininosuccinate and rendering the FH-deficient cells auxotrophic for arginine and sensitive to pharmacological arginine depletion from the growth media compared with controls (91, 92). Argininosuccinate accumulation was also detected in kidney and urine samples of Fh1-deficient mice, raising its potential as a biomarker for HLRCC (91, 92). Further, re-expression of cytosolic FH in vivo ameliorated both renal cyst development and urea cycle defects observed in mice with renal-specific Fh1 deletion, implicating a potential role for extra-mitochondrial metabolic pathways in FH-associated oncogenesis (92).

**Biomarkers**

IDH mutations correlate with better survival of glioma patients (93), hence assessment of IDH mutation status carries significant diagnostic and prognostic value. Techniques for routine neuropathological detection of IDH mutations include DNA-based sequencing approaches and immunohistochemistry (IHC) staining using mutation-specific antibodies (94–97). However, there are at least five reproducible cancer-associated mutations that can result in 2HG production, and further, con-
atorial gene sequencing methods may lead to false positives
due to genetic polymorphism and sequencing artifacts (98). In
comparison, screening for elevated 2HG levels is a sensitive and
specific approach to detect IDH mutations in tumors. Whereas
patient sera/plasma can be assessed in the case of AML (7, 8,
21, 99), exciting advances with proton magnetic resonance spec-
troscopy (MRS) have been made in the noninvasive detection of
2HG in patients with gliomas (100–103). Using MRS sequence
optimization and spectral fitting techniques, Maher and col-
leagues examined 30 patients with glioma and showed that the
detection of 2HG correlated 100% with the presence of IDH1 or
IDH2 mutations (102). Andronesi et al. further demonstrated
that two-dimensional correlation spectroscopy could effectively
distinguish 2HG from chemically similar metabolites present
in the brain (103).

Negative IHC staining for SDHB correlates with the presence
of SDH mutations, whether in SDHB, SDHC, or SDHD (104).
This finding is most likely explained by the fact that mutations
in any of the four subunits of SDH can destabilize the entire
enzyme complex. PGLs/PCCs associated with an SDHA muta-
tion show negative staining for SDHA as well as SDHB (105).
Therefore, IHC staining for SDHB is a useful diagnostic tool
to triage patients for genetic testing of any SDH mutation, and
subsequent staining for the other subunits may further narrow
the selection of genes to be tested. In contrast, detection of FH
protein is often evident in HLRCC tumors due to retention of
the nonfunctional mutant allele (106). However, staining of cysts
and tumors for 2SC immunoreactivity reveals a striking correla-
tion between FH inactivation and the presence of 2SC-modified
protein (2SCP), which is absent in non-HLRCC tumors and nor-
mal tissue controls (106). IHC staining for 2SCP thus provides a
robust diagnostic biomarker for FH deficiency (107).

Therapeutic targeting

Because D-2HG is a product of neomorphic enzyme activities,
curtailed the D-2HG supply by specifically inhibiting the mutant
IDH enzymes provides an elegant approach to target IDH-mutant
cancers. Indeed, recent reports of small-molecule inhibitors
against mutant forms of IDH1 and IDH2 demonstrated the fea-
sibility of this method. An inhibitor against IDH2 R140Q was
shown to reduce both intracellular and extracellular levels of
D-2HG, suppress cell growth, and increase differentiation of
primary human AML cells (108). Similarly, small-molecule inhibi-
tion of IDH1 R132H suppressed colony formation and increased
tumor cell differentiation in a xenograft model for IDH1 R132H
glioma (58). The inhibitors exhibited a cytostatic rather than
cytotoxic effect, and therefore their therapeutic efficacy over lon-
ger time periods may need further assessment (109). Letouzé et
al. showed that the DNA methyltransferase inhibitor decitabine
could repress the migration capacities of SDHB-mutant cells (40).
However, for SDH- and FH-associated cancers, a synthetic lethal-
ity approach is worth exploring because of the pleiotropic effects
associated with succinate and fumarate accumulation.

Outlook

The application of next-generation sequencing technologies in the
field of cancer genomics has substantially increased our under-
standing of cancer biology. Detection of germline and somatic
mutations in specific tumor types not only expands the current
repertoire of driver mutations and downstream effectors in tumor-
igenesis, but also sheds light on how oncometabolites may exert
their oncogenic roles. For example, the identification of mutually
exclusive mutations in IDH1 and TET2 in AML led to the char-
acterization of TET2 as a major pathological target of D-2HG
(34, 110). Additionally, the discovery of somatic CUL3, SIRT1, and
NRFP2 mutations in sporadic PRCC2 converges with FH mutation
in HLRCC, in which NRFP2 activation is a consequence of fuma-
rate-mediated succination of KEAP1, indicating the functional
prominence of the NRF2 pathway in PRCC2 (73). In light of this,
the identification of somatic mutations in genes encoding the
chromatin-modifying enzymes histone H3K36 methyltransferase
(SETD2), histone H3K4 demethylase JARID1C (KDM5C), histone
H3K27 demethylase UTX (KDM6A), and the SWI/SNF chromatin
remodelling complex gene PBRM1 in clear cell renal cell carcino-
oma (111–113) highlights the importance of epigenetic modulation
in human cancer and raises the potential for systematic testing in
other types of tumors such as those associated with FH mutations.

Technological advances such as those in gas and liquid-
chromatography mass spectrometry (114, 115) and nuclear
magnetic resonance imaging (102) have greatly improved the
ability to measure low-molecular-weight metabolites in tumor
samples with high resolution (116). Combined with metabolic
flux analyses employing isotope tracers and mathematical mod-
ing, modern-era metabolomic approaches can provide direct
pathophysiological insights into tumor metabolism and serve as
an excellent tool for biomarker discovery. Using a data-driven
approach, Jain and colleagues constructed the metabolic profiles
of 60 cancer cell lines and discovered glycine consumption as a
key metabolic event in rapidly proliferating cancer cells (117),
thus demonstrating the power of metabolomic analyses and the
relevance to future cancer research and therapeutics.

Acknowledgments

The Cancer Biology and Metabolism Group is funded by Cancer
Research UK and the European Research Council under the Euro-
pean Community’s Seventh Framework Programme (FP7/2007-
2013)/ERC grant agreement no. 310837 to Dr. Pollard. Professor
Soga receives funding from a Grant-in-Aid for scientific research
on Innovative Areas, Japan (no. 22134007), and the Yamagata Pre-
fectoral Government and City of Tsuruoka.

Address correspondence to: Patrick J. Pollard, Cancer Biol-
ogy and Metabolism Group, Nuffield Department of Medicine,
Henry Wellcome Building for Molecular Physiology, Univer-
sity of Oxford, Roosevelt Drive, Oxford, OX3 7BN, United King-
don. Phone: 44.01865287780; Fax: 44.01865287787; E-mail:
patrick.pollard@well.ox.ac.uk.

1. Yang M, Soga T, Pollard PJ, Adam J. The emerging
role of fumarate as an oncometabolite. Front Oncol.
2012;2:85.
2. Ward PS, Thompson CR. Metabolic reprogram-
m: a cancer hallmark even warburg did not
3. Vander Heiden MG, Cantley LC, Thompson CB.
Understanding the Warburg effect: the metabolic
requirements of cell proliferation. Science. 2009;
324(5930):1029–1033.
4. Thompson CB. Metabolic enzymes as onco-
5. Schulze A, Harris AL. How cancer metabolism is
tuned for proliferation and vulnerable to disrup-
intermediates and over-expression of HIF1alpha
in tumours which result from germline FH and
7. Ward PS, et al. The common feature of leukemia-
associated IDH1 and IDH2 mutations is a neo-
orphic enzyme activity converting alpha-keto-

3656   The Journal of Clinical Investigation  http://www.jci.org Volume 123   Number 9   September 2013


81. Ishii T, Yasuda K, Akatsu A, Hino O, Hartmann C. Type and frequency of IDH1 and IDH2 mutations associated with oncogenic signal that induces IL-1β through HIF-1α. Oncogene. 2011;30(5):117–123.


